Adrián Curran

Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations

Judith Grau-Expósito, Laura Luque-Ballesteros, Jordi Navarro et al. · PLoS Pathogens · 2019 · 157 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial

José Ramón Santos, María Saumoy, Adrián Curran et al. · Clinical Infectious Diseases · 2015 · 140 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +5

A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4 ⁺ T cells as a Major Niche for HIV-1 Transcription in HIV-Infected Patients

Judith Grau-Expósito, Carla Serra‐Peinado, L. Miguel et al. · mBio · 2017 · 111 citations · Full text

Life Sciences, Immunology, Molecular Biology +16

Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study

Daniel K. Nomah, Juliana Reyes‐Urueña, Yesika Díaz et al. · The Lancet HIV · 2021 · 110 citations · Full text

Public Health, Health Sciences, Infectious Diseases +17

Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial

Federico Pulido, Esteban Ribera, María Lagarde et al. · Clinical Infectious Diseases · 2017 · 102 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17